MAPT and Alzheimer disease: Here, we examine the associations of the APOE ε2 and ε4 alleles and the AD-risk-differentiating compound genotypes comprising rs429358, rs2075650, and rs12721046 SNPs with Aβ40, Aβ42, and tau AD biomarkers measured in CSF and plasma using data from three studies: the AD Neuroimaging Initiative (ADNI), the Atherosclerosis Risk in Communities (ARIC) study, and the Framingham Heart Study (FHS).